A few sequential studies comparing paired patient samples at the time of CMML diagnosis and at AML transformation have postulated a key role for the RAS pathway and for mutations in EZH2, IDH1/2, NPM1, and FLT3-ITD [14,50]. This evidence concerns the gene IDH1 and acute myeloid leukemia.